Caraco Pharmaceutical Laboratories

Caraco Pharmaceutical Laboratories (United States) holds 0 active US FDA Type II Drug Master Files and 1 inactive. 12 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “Caraco Pharmaceutical Laboratories: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/caraco-pharmaceutical-laboratories

Overview

Caraco Pharmaceutical Laboratories is a pharmaceutical company headquartered in Detroit, United States.

API / Drug Master Files

Caraco Pharmaceutical Laboratories holds 0 active (1 total) FDA Type II Drug Master File. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.

  • FACILITY IN DETROIT, MICHIGAN.Inactive1992-10-24

FDA compliance signals

12 FDA enforcement records linked to this company.

  • recall — Class II2014-08-13

    CGMP Deviations: These products are being recalled because they were manufactured with active pharmaceutical ingredients (APIs) that were not manufactured with good manufacturing practices.

  • recall — Class II2014-08-13

    CGMP Deviations: These products are being recalled because they were manufactured with active pharmaceutical ingredients (APIs) that were not manufactured with good manufacturing practices.

  • recall — Class II2014-07-09

    Failed Dissolution Specifications: Stability results found the product did not meet the drug dissolution specifications.

  • recall — Class II2014-07-02

    Lack of Assurance of Sterility: A particle excursion for a different batch of the same product may lead to a lack of sterility assurance.

  • recall — Class II2014-05-07

    Failed Dissolution Specifications: Stability results found the product did not meet the drug release dissolution specifications.

  • recall — Class II2014-05-07

    Failed Dissolution Specifications: Stability results found the product did not meet the drug release dissolution specifications.

  • recall — Class III2014-05-07

    Failed Impurities/Degradation Specifications: out of specification results for impurities/degradation testing for N-Oxide

  • recall — Class III2014-05-07

    Failed Impurities/Degradation Specifications: out of specification results for impurities/degradation testing for N-Oxide

  • recall — Class II2014-03-05

    Presence of Foreign Tablet; customer complaint of some tablets of Gabapentin found in a bottle of Metformin HCl ER

  • recall — Class II2014-02-19

    Failed Tablet Specifications: Broken Tablets Present.

  • recall — Class II2012-12-12

    Adulterated Presence of Foreign Tablets: A customer complaint was received that a bottle of Tramadol HCl Tablets USP 50 mg contained some tablets of Metoprolol Tartrate Tablets USP, 50 mg.

  • recall — Class II2012-10-10

    Crystallization: Presence of crystals of Nimodipine within the capsule solution.

For suppliers

Is this Caraco Pharmaceutical Laboratories?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.